{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"description":"Defined as unilineage or multilineage recovery by 1 or more of the following: 1) platelet response (increase to 20 × 103/μL above baseline or stable platelet counts with transfusion independence for a minimum of 8 weeks in those who were transfusion dependent on entry into the protocol); (2) erythroid response (when pretreatment hemoglobin was \\<9 g/dL, defined as an increase in hemoglobin by 1.5 g/dL or, in transfused patients, a reduction in the units of packed red blood cell transfusions by an absolute number of at least 4 transfusions for 8 consecutive weeks, compared with the pretreatment transfusion number in the previous 8 weeks); and (3) neutrophil response (when pretreatment absolute neutrophil count \\[ANC\\] of \\<0.5 × 103/μL as at least a 100% increase in ANC, or an ANC increase \\>0.5 × 103/μL, and the toxicity profile as measured using Common Terminology Criteria for Adverse Events).","groups":[{"description":"Eltrombopag (Promacta): Subjects commenced eltrombopag at a dose of 50 mg, which was increased by 25 mg every 2 weeks if the platelet count had not increased by 20 × 103/µL, to a maximum dose of 150 mg.","id":"OG000","title":"Eltrombopag"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All subjects who received Eltrombopag were analyzed.","reportingStatus":"POSTED","timeFrame":"12-16 weeks","title":"The Portion of Drug Responders as Defined by Hematologic Improvements","type":"PRIMARY","unitOfMeasure":"Participants"}